Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients

ConclusionThe DR of [18F]AlF-OC was numerically higher and non-inferior to the DR of [68Ga]Ga-DOTATATE. [18F]AlF-OC lesions and especially incremental lesions were confirmed as true positives by MRI in more than 90% of lesions. Taken together, these data further validate [18F]AlF-OC as a new alternative for SSTR PET in clinical practice.Trial registration ClinicalTrials.gov: NCT04552847. Registered 17 September 2020,https://beta.clinicaltrials.gov/study/NCT04552847

http://link.springer.com/10.1186/s13550-023-01003-3

Source: EJNMMI Research - June 1, 2023 Category: Radiology Source Type: research